- Home
- VEEA vs EPRX Comparison
VEEA vs EPRX Comparison
Compare VEEA & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEEA
- EPRX
- Stock Information
- Founded
- VEEA 2014
- EPRX 2011
- Country
- VEEA United States
- EPRX Canada
- Employees
- VEEA N/A
- EPRX N/A
- Industry
- VEEA
- EPRX
- Sector
- VEEA
- EPRX
- Exchange
- VEEA NYSE
- EPRX NYSE
- Market Cap
- VEEA 84.8M
- EPRX 85.5M
- IPO Year
- VEEA N/A
- EPRX N/A
- Fundamental
- Price
- VEEA $2.52
- EPRX $3.49
- Analyst Decision
- VEEA
- EPRX
- Analyst Count
- VEEA 0
- EPRX 0
- Target Price
- VEEA N/A
- EPRX N/A
- AVG Volume (30 Days)
- VEEA 394.2K
- EPRX 33.3K
- Earning Date
- VEEA 11-20-2024
- EPRX 11-07-2024
- Dividend Yield
- VEEA N/A
- EPRX N/A
- EPS Growth
- VEEA N/A
- EPRX N/A
- EPS
- VEEA N/A
- EPRX N/A
- Revenue
- VEEA $140,035.00
- EPRX N/A
- Revenue This Year
- VEEA N/A
- EPRX N/A
- Revenue Next Year
- VEEA N/A
- EPRX N/A
- P/E Ratio
- VEEA N/A
- EPRX N/A
- Revenue Growth
- VEEA N/A
- EPRX N/A
- 52 Week Low
- VEEA $2.14
- EPRX $2.20
- 52 Week High
- VEEA $18.56
- EPRX $4.08
- Technical
- Relative Strength Index (RSI)
- VEEA N/A
- EPRX N/A
- Support Level
- VEEA N/A
- EPRX N/A
- Resistance Level
- VEEA N/A
- EPRX N/A
- Average True Range (ATR)
- VEEA 0.00
- EPRX 0.00
- MACD
- VEEA 0.00
- EPRX 0.00
- Stochastic Oscillator
- VEEA 0.00
- EPRX 0.00
About VEEA VEEA INC
Veea Inc is a company providing edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. It has first-in-class VeeaHub smart computing hubs integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.